MD

Veradigm IncMOEX MDRX-RM Stock Report

Last reporting period 30 Sep, 2022

Updated —

Last price

Market cap $B

1.066

Small

Exchange

MISX - Moscow Exchange

MDRX-RM.ME Stock Analysis

MD

Neutral

Based on Eyestock quantitative analysis, MDRX-RM.ME`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

61/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-62.1 %

Overvalued

Market cap $B

1.066

Dividend yield

Shares outstanding

109.26 B

Veradigm, Inc. engages in the provision of clinical, financial, and operational results services. The company is headquartered in Chicago, Illinois and currently employs 8,000 full-time employees. The firm's solutions helps to connect people, places and data across an Open Connected Community of Health. The company offers payer and life sciences solutions, which are mainly targeted at payers, life sciences companies and other key healthcare stakeholders. Veradigm also offers software applications for patient engagement and the sale of electronic health record (EHR) software to single-specialty and small and mid-sized physician practices, including related clinical, financial, administrative and operational solutions.

View Section: Eyestock Rating